Medicenna Therapeutics (TSE:MDNA) Sets New 52-Week Low – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as C$0.34 and last traded at C$0.34, with a volume of 9582 shares traded. The stock had previously closed at C$0.35.

Medicenna Therapeutics Price Performance

The stock’s 50-day moving average is C$0.42 and its 200 day moving average is C$0.65. The company has a debt-to-equity ratio of 4.79, a current ratio of 1.52 and a quick ratio of 4.65. The company has a market cap of C$31.84 million, a PE ratio of -1.57 and a beta of 2.96.

Medicenna Therapeutics (TSE:MDNA) last released its quarterly earnings results on Thursday, June 25th. The company reported C($0.05) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 219.30% and a negative net margin of 533,640.00%. On average, equities analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.